This article shares a common deficit with many other reports addressing cost-effectiveness of the medications used to treat schizophrenia. It is clearly true that the newer medications are much more expensive than the older ones, but tardive dyskinesia (TD) rates have plummeted by about 99 percent with the advent of the modern antipsychotic medications.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.